AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8160789
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of endothelin-1 (ET-1)
Trial: 28987930
Drug: new drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: new drugs
Trial: 28583653
Drug: Prospectively ECG‐triggered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prospectively ECG‐triggered high‐pitch CCTA at 70 kVp with 30mL contrast agent (protocol A)
Trial: 28583653
Drug: Prospectively ECG‐triggered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prospectively ECG‐triggered sequential scanning at 120 kVp and 60mL contrast medium (protocol B)
Trial: 24059131
Drug: Timely ovulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timely ovulation induction with clomiphene citrate tablets at the first menstrual cycle post-operation
Trial: 24059131
Drug: Expectant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expectant treatment only
Trial: 21403575
Drug: Amoxicillin 1
RxNorm normalized name: amoxicillin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 1 g orally 1 h before surgery
Trial: 21403575
Drug: Metronidazole 800
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole 800 mg orally 1 h before surgery
Trial: 10740162
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium (15 g over a 48-hour period)
Trial: 10740162
Drug: Placebo (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intravenous dextrose solution)
Trial: 1313549
Drug: Ganciclovir (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganciclovir (5 mg/kg every 12 hours for 14 days, then 6 mg/kg daily for 5 days per week until day 28)
Trial: 27514617
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg clopidogrel
Trial: 18765393
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg clopidogrel
Trial: 18765393
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg clopidogrel (after initial loading)
Trial: 7676980
Drug: 3 ml/sec
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml/sec uniphasic
Trial: 7676980
Drug: 2 ml/sec
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml/sec uniphasic
Trial: 7676980
Drug: 3 ml/sec
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml/sec biphasic
Trial: 2161058
Drug: Pipecuronium bromide
RxNorm normalized name: pipecuronium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pipecuronium bromide (PPB) 0.01 mg.kg-1
Trial: 2161058
Drug: Pipecuronium bromide
RxNorm normalized name: pipecuronium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pipecuronium bromide (PPB) 0.05 mg.kg-1 or 0.1 mg.kg-1
Trial: 2161058
Drug: Pancuronium bromide
RxNorm normalized name: Pancuronium Bromide
DrugBank: Pancuronium (DB01337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pancuronium bromide (PCB) 0.01 mg.kg-1
Trial: 30630161
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (40 IU, n = 29)
Trial: 23168378
Drug: New magnetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New magnetic suspension system
Trial: 16092057
Drug: Micronized fenofibrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized fenofibrate (200 mg/d)
Trial: 16092057
Drug: Atorvastatin and
RxNorm normalized name: atorvastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin and micronized fenofibrate (combination)
Trial: 12893114
Drug: Biomedical, psychosocial,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biomedical, psychosocial, and combined medical-psychosocial approaches to treatment
Trial: 10553851
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion at 0.125 microg x kg(‐1) x min(‐1) (Group 2)
Trial: 10553851
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion at 0.0625 microg x kg(‐1) x min(‐1) (Group 1)
Trial: 10553851
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion at 0.250 microg x kg(‐1) x min(‐1) (Group 3)
Trial: 15278644
Drug: Intravenous aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous aspirin DL‐lysine 900 mg (equivalent to aspirin 495 mg)
Trial: 6689676
Drug: Nifedipine 40
RxNorm normalized name: nifedipine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 40 mg
Trial: 19364966
Drug: Trastuzumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab (1 year after chemotherapy)
Trial: 17331237
Drug: Collaborative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative care approach including Problem Solving Treatment and antidepressant treatment algorithm
Trial: 15372171
Drug: Hyoid suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoid suspension surgery
Trial: 20525211
Drug: A allele
RxNorm normalized name: Human leucocyte antigen A allele
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A allele of the angiotensin II type 1 receptor
Trial: 12574224
Drug: Hyperthyroid patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperthyroid patients before treatment
Trial: 12574224
Drug: Hyperthyroid patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperthyroid patients during treatment
Trial: 12574224
Drug: Hyperthyroid patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperthyroid patients after treatment
Trial: 8867434
Drug: iomeprol 350
RxNorm normalized name: Iomeprol 350 MG/1 ML Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iomeprol 350 mg/ml
Trial: 8867434
Drug: iopentol 350
RxNorm normalized name: iopentol 350 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iopentol 350 mg/ml
Trial: 1653674
Drug: Insulin (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (0.15 units/kg)
Trial: 3880557
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg daily, morning dosage at 9 am for 5 days)
Trial: 3880557
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg daily, evening dosage at 9 pm for 5 days)
Trial: 3880557
Drug: Omeprazole (morning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (morning dosage)
Trial: 3880557
Drug: Omeprazole (evening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (evening dosage)
Trial: 17913970
Drug: Ciprofloxacin 750
RxNorm normalized name: ciprofloxacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 750 mg alone
Trial: 17913970
Drug: Ciprofloxacin 750
RxNorm normalized name: ciprofloxacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 750 mg plus lanthanum carbonate 1 g three times daily with meals
Trial: 11389423
Drug: Chronic venous
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic venous ulcer wound fluid (CVUWF, 300 microg protein/mL)
Trial: 11445756
Drug: Creatine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine (0.3 g.kg(‐1) Cr monohydrate for 7 days)
Trial: 29458447
Drug: Self-monitoring urinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-monitoring urinary salt excretion using a self-measuring device for 4 weeks
Trial: 29458447
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (urine salt excretion measured but results not disclosed)
Trial: 15938536
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of lisinopril with indapamid
Trial: 15938536
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of egilok+hypothiaside
Trial: 15938536
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of diroton+indap
Trial: 15938536
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cordipin-retard+hypothiaside
Trial: 15938536
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of renitek-hypothiaside
Trial: 12117883
Drug: L-NMMA 4
RxNorm normalized name: 4-hydroxy-L-phenylalanine
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-NMMA 4 mg/kg/h
Trial: 12117883
Drug: L-NMMA 8
RxNorm normalized name: 8-L-lysinevasopressin
DrugBank: Lypressin (DB14642)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-NMMA 8 mg/kg/h
Trial: 2349371
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg naloxone intravenous injection
Trial: 26755382
Drug: Tocilizumab (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (40 mg) + 1-2 mL of 0.5% bupivacaine
Trial: 20110402
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment at a dose of 2 mg/m(2) per day until the onset of puberty for at least 2 years.
Trial: 16392436
Drug: Pumpan® (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pumpan® (3 × 10 drops daily for 6 weeks)
Trial: 30888835
Drug: HCL AP
RxNorm normalized name: AP-101
DrugBank: AP-101 (DB17947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCL AP therapy with the Control-IQ system
Trial: 30888835
Drug: SAP therapy
RxNorm normalized name: Bambusa vulgaris sap extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAP therapy with remote monitoring
Trial: 22864520
Drug: Adrenalized infraclavicular
RxNorm normalized name: adrenal cortex extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenalized infraclavicular lidocaine 2% 10 ml + ropivacaine 0.75% 20 ml ('long acting', n=90)
Trial: 22864520
Drug: Adrenalized infraclavicular
RxNorm normalized name: adrenal cortex extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenalized infraclavicular lidocaine 1.5% 30 ml + long-acting distal median, radial, and ulnar nerve blocks ('short acting', n=87)
Trial: 20143047
Drug: Combined drug
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined drug and behavioral therapy
Trial: 17650661
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) treatment (5‐10 mA, 80‐100 Hz, 30 min stimulation, once daily for 10 days)
Trial: 17650661
Drug: Cetirizine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (10 mg/times, t.i.d, peros)
Trial: 12234851
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream applied one time per week
Trial: 12234851
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream applied two times per week
Trial: 12234851
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream applied three times per week
Trial: 12234851
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream (all dosing regimens)
Trial: 9612628
Drug: Various antibiotics
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various antibiotics
Trial: 7817332
Drug: Benzodiazepine (lormetazepam,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzodiazepine (lormetazepam, 2 mg)
Trial: 16245354
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) for 5 years (20 mg/day)
Trial: 16245354
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) for 2 years (20 mg/day)
Trial: 11886196
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (SC and CC)
Trial: 7660449
Drug: 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg DEC once daily for 12 days
Trial: 7660449
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg DEC given 3 times daily for 12 days
Trial: 7660449
Drug: All 3
RxNorm normalized name: Small 33G Lancet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All 3 treatment regimens (6 mg/kg once daily, 2 mg/kg three times daily, and unspecified third regimen)
Trial: 2913493
Drug: Outpatient detoxification
RxNorm normalized name: ARTEMISIA VULGARIS ROOT 4.5 mg in 30 mg / CINNAMON 3 mg in 30 mg / CALENDULA OFFICINALIS FLOWER 4.5 mg in 30 mg / MENTHA PIPERITA LEAF 9 mg in 30 mg TOPICAL LIQUID [HOUKEA Lymphatic Detoxification Anti-Inflammatory Slimming Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient detoxification with decreasing doses of oxazepam
Trial: 2913493
Drug: Inpatient detoxification
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient detoxification with oxazepam and rehabilitation treatment
Trial: 972787
Drug: Oral riboflavin
RxNorm normalized name: riboflavin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral riboflavin with blue light energy of 6-7 muW/cm2
Trial: 7303703
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg beta‐methyldigoxin (Lanitop) daily, orally
Trial: 7303703
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg beta‐acetyldigoxin (Novodigal) daily, orally
Trial: 15078004
Drug: Clarithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (500 mg b.i.d. x 7 days)
Trial: 15078004
Drug: Amoxicillin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (1 g t.i.d. x 7 days)
Trial: 9919896
Drug: Itraconazole 400
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole 400 mg daily for 1 week
Trial: 8186139
Drug: Itraconazole 100
RxNorm normalized name: itraconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 100 mg daily for 4 weeks
Trial: 8311214
Drug: Intra-articular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular morphine (1 mg)
Trial: 3138057
Drug: Vamin 14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vamin 14 infusion
Trial: 28314613
Drug: Ultra-low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low dose (ULD) protocols (I: 100kVp/50 mAs, II: 100kVp/75 mAs, III: 100kVp/100 mAs, IV: 120kVp/100 mAs)
Trial: 28314613
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (LD) protocols (I: 100kVp/75 mAs, II: 100kVp/100 mAs, III: 100kVp/150 mAs, IV: 120kVp/150 mAs)
Trial: 16731321
Drug: Cisatracurium plus
RxNorm normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisatracurium plus 3 mg/kg lidocaine
Trial: 16731321
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (3 mg/kg lidocaine diluted with saline)
Trial: 15256690
Drug: Acute Rhodiola
RxNorm normalized name: RHODIOLA ROSEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute Rhodiola rosea intake (200 mg extract containing 3% rosavin + 1% salidroside)
Trial: 15256690
Drug: Acute Rhodiola
RxNorm normalized name: RHODIOLA ROSEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute Rhodiola rosea intake (200 mg extract)
Trial: 8858190
Drug: Dopamine agonists
RxNorm normalized name: Dopamine agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine agonists (pergolide, bromocriptine, cabergoline)
Trial: 8858190
Drug: Catechol-O-methyltransferase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catechol-O-methyltransferase inhibitors (tolcapone, entacapone)
Trial: 8858190
Drug: Selegiline therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline therapy
Trial: 1862015
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg ibuprofen controlled-release tablet (CRT)
Trial: 1862015
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg ibuprofen controlled-release tablet (CRT)
Trial: 6869899
Drug: Cimetidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (300 mg orally the evening before and 300 mg intramuscularly between 1 and 3 h preoperatively)
Trial: 6869899
Drug: Antacid (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid (30 ml of Mylanta-II orally on both occasions)
Trial: 18838500
Drug: Dopamine agonist
RxNorm normalized name: Dopamine agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine agonist (pramipexole 0.5 mg)
Trial: 18838500
Drug: Dopamine antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine antagonist (sulpiride 400 mg)
Trial: 12904518
Drug: Estrogen therapy
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen therapy with micronized 17beta‐estradiol alone
Trial: 12904518
Drug: 17beta‐estradiol plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17beta‐estradiol plus sequentially administered medroxyprogesterone acetate
Trial: 8889422
Drug: Priming dose
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Priming dose of 0.01 mg kg‐1 followed by 0.07 mg kg‐1 after 3-4 min
Trial: 8889422
Drug: Priming dose
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Priming dose of 0.015 mg kg‐1 followed by 0.065 mg kg‐1 after 3-4 min
Trial: 8889422
Drug: Single bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single bolus injection of 0.08 mg kg‐1
Trial: 6308441
Drug: Ketoconazole 400
RxNorm normalized name: ketoconazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole 400 mg daily p.o.
Trial: 31192738
Drug: 5 ml
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml of honey with an ORS at every diarrhea episode
Trial: 31192738
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of honey added to an ORS at every diarrhea episode
Trial: 24578471
Drug: 1.4% sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.4% sodium bicarbonate hydration (250 mL) prior to CE-CT
Trial: 24578471
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline hydration (1000 mL) prior to and after CE-CT
Trial: 20579907
Drug: Standard Treatment
RxNorm normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard Treatment Group
Trial: 16117878
Drug: Prophylactic cranial
RxNorm normalized name: geranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic cranial irradiation (PCI) at a dose of 25.2 to 30.6 Gy in 1.8 to 2.0 Gy per fraction
Trial: 1440822
Drug: Albendazole 400
RxNorm normalized name: albendazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole 400 mg once daily for 21 days
Trial: 3698061
Drug: Wax/polymer matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wax/polymer matrix tablet 60 mEq/day (20 mEq TID)
Trial: 3698061
Drug: Powder-in-liquid formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder-in-liquid formulation 60 mEq/day (20 mEq TID)
Trial: 29383408
Drug: 400 IU
RxNorm normalized name: Vitamin D 400 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 IU of nasal salmon calcitonin daily for three months
Trial: 18425398
Drug: UFT (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT (300 mg/day, three days after TACE)
Trial: 12892766
Drug: Intracoronary radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary radiation therapy (IRT) with Sr-90
Trial: 10848883
Drug: DHEA 50
RxNorm normalized name: Natrol Mood & Stress DHEA 50mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA 50 mg and 200 mg
Trial: 9665269
Drug: BPI treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPI treatment
Trial: 8172749
Drug: Iopentol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iopentol (300 mg I/ml), 2 ml/kg b.w. with an upper limit of 100 ml
Trial: 8172749
Drug: Iohexol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iohexol (300 mg I/ml), 2 ml/kg b.w. with an upper limit of 100 ml
Trial: 23553534
Drug: Intravenous zanamivir
RxNorm normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous zanamivir 1200 mg
Trial: 23553534
Drug: Intravenous zanamivir
RxNorm normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous zanamivir placebo